Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma
a technology of melanoma and inhibitory activity, which is applied in the field of melanoma inhibitory activity (mia) protein as an early indicator, can solve the problems of poor prognosis of patients with disseminated disease and the acute need for new therapies
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
[0059]This Example demonstrates that MIA is expressed in and secreted from human melanoma cell lines and is not expressed in human colorectal cancer cell lines.
[0060]Methods:
[0061]Cell Lines:
[0062]The human melanoma cell lines, G361, SKMEL-28 and CHL-1; and colon carcinoma cell line, HCT-116, were obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). The human melanoma cell line A375M and the human colon carcinoma cell line HT-29P were obtained from the University of Texas, M.D. Anderson Cancer Center (Houston, Tex.).
[0063]Cell Culture:
[0064]The G361, A375M and HT-29P cell lines were cultured in McCoy's 5A medium; the SKMEL-28 cell line was maintained in Minimum Essential Medium (MEM); the CHL-1 cell line was grown in Dulbecco's Modification of Eagle's Medium (DMEM); and the HCT-116 cell line was cultured in RPMI 1640 medium. All cell culture media was supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1×MEM vitamins, 1×MEM amino a...
example 2
[0073]This Example demonstrates that MIA may be used as a surrogate marker for tumor burden in human melanoma tumor-bearing mice.
[0074]Methods:
[0075]Animal Models:
[0076]An A375 human melanoma xenograft study was carried out with female athymic nu / nu mice (8-12 weeks old) purchased from Charles River Laboratories (Wilmington, Mass.). Approximately 2.5×106 cells were implanted subcutaneously (s.c.) into the hind flank region of mice. Plasma samples were collected when tumors reached an average size of 250 mm3 (n=10) and stored at −80° C. prior to MIA analysis. Dosing typically began when tumors reached an average size of 250 mm3. Plasma samples from non-tumor-bearing (naïve) mice (n=4) were also collected for comparison, as shown in FIG. 3. Caliper measurements were performed twice weekly to estimate tumor volume using the formula: (a×b2)×0.5, where “a” is the largest diameter and “b” is the length perpendicular to the diameter.
[0077]An MEXF 276 human melanoma tumor explant xenograft ...
example 3
[0090]This Example demonstrates that MIA is a early and accurate indicator for anti-tumor drug activity in preclinical melanoma models.
[0091]Methods:
[0092]The kinetics of MIA concentrations in plasma following drug treatment were investigated as follows. A375M tumor-bearing mice were dosed orally either with CHIR-265 (100 mg / kg), CHIR-258 (60 mg / kg) or vehicle (n=10 / group). Plasma samples were collected before dosing was initiated, and again on day 3, 8 and 13. Tumor volumes were measured at the same time points, using methods described in EXAMPLE 2.
[0093]Results:
[0094]FIG. 5A graphically illustrates the early and significant changes in MIA plasma levels in response to treatment with CHIR-258 and CHIR-265 in the A375M human melanoma xenograft model. *P<0.05 for all comparisons vs. vehicle. Error bars indicate standard errors (SE). The dashed line indicates the detection limit of the assay.
[0095]FIG. 5B shows the tumor volumes in the A375M human melanoma tumor bearing mice at day 3, ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More